Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;76(2):134-144.
doi: 10.1055/s-0041-111788.

Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)

C Tempfer  1 , L-C Horn  2 , S Ackermann  3 , M W Beckmann  4 , R Dittrich  4 , J Einenkel  5 , A Günthert  6 , H Haase  7 , J Kratzsch  8 , M C Kreissl  9 , S Polterauer  10 , A D Ebert  11 , K T M Schneider  12 , H G Strauss  13 , F Thiel  14
Affiliations

Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)

C Tempfer et al. Geburtshilfe Frauenheilkd. 2016 Feb.

Abstract
in English, German

Purpose: The aim was to establish an official interdisciplinary guideline, published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). The guideline was developed for use in German-speaking countries. In addition to the Germany Society of Gynecology and Obstetrics, the guideline has also been approved by the Swiss Society of Gynecology and Obstetrics (SGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). The aim was to standardize diagnostic procedures and the management of gestational and non-gestational trophoblastic disease in accordance with the principles of evidence-based medicine, drawing on the current literature and the experience of the colleagues involved in compiling the guideline. Methods: This s2k guideline represents the consensus of a representative panel of experts with a range of different professional backgrounds commissioned by the DGGG. Following a review of the international literature and international guidelines on trophoblastic tumors, a structural consensus was achieved in a formalized, multi-step procedure. This was done using uniform definitions, objective assessments, and standardized management protocols. Recommendations: The recommendations of the guideline cover the epidemiology, classification and staging of trophoblastic tumors; the measurement of human chorionic gonadotropin (hCG) levels in serum, and the diagnosis, management, and follow-up of villous trophoblastic tumors (e.g., partial mole, hydatidiform mole, invasive mole) and non-villous trophoblastic tumors (placental site nodule, exaggerated placental site, placental site tumor, epitheloid trophoblastic tumor, and choriocarcinoma).

Ziel: Erstellung einer offiziellen, internationalen, interdisziplinären Leitlinie, publiziert und koordiniert von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Die Leitlinie wurde für den deutschsprachigen Raum entwickelt und wird neben der DGGG auch von der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) und der Österreichischen Geselllschaft für Gynäkologie und Geburtshilfe (OEGGG) mitgetragen. Ziel der Leitlinie war es, die Diagnostik und Therapie von gestationsbedingten und nicht gestationsbedingten Trophoblasterkrankungen anhand der aktuellen Literatur sowie der Erfahrung der beteiligten Kolleginnen und Kollegen evidenzbasiert zu standardisieren. Methoden: Anhand der internationalen Literatur und unter Verwendung internationaler Leitlinien zum Thema Trophoblasttumore entwickelten die Mitglieder der beteiligten Fachgesellschaften im Auftrag der Leitlinienkommission der DGGG in einem strukturierten Prozess einen formalen Konsensus. Dies erfolgte unter Verwendung von einheitlichen Definitionen, objektivierten Bewertungsmöglichkeiten und standardisierten Therapieprotokollen. Empfehlungen: Die Empfehlungen der Leitlinie betreffen die Epidemiologie, Klassifikation und Stadieneinteilung von Trophoblasttumoren, die Bestimmung von humanem Choriongonadotropin (hCG) sowie die Diagnose, Therapie und Nachsorge von villösen Trophoblasttumoren (Partialmole, Blasenmole, invasive Mole) und nicht villösen Trophoblasttumoren (Plazentabett-Knoten, hyperplastische Implantationsstelle, Plazentabett-Tumor, epitheloider Trophoblasttumor und Chorionkarzinom).

Keywords: human chorionic gonadotropin; hydatidiform mole; mole; treatment recommendations; trophoblastic tumor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Classification of gestational trophoblastic disease (GTD) according to clinical and pathobiological criteria based on the classification of the World Health Organization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mangili G, Lorusso D, Brown J. et al.Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer. 2014;24(9 Suppl. 3):S109–S116. - PubMed
    1. Seckl M J, Sebire N J, Fisher R A. et al.ESMO Guidelines Working Group . Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 06:vi39–vi50. - PubMed
    1. Ngan H Y, Bender H, Benedet J L. et al.FIGO Committee on Gynecologic Oncology . Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83 01:175–177. - PubMed
    1. El-Helw L M, Coleman R E, Everard J E. et al.Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia. Gynecol Oncol. 2009;113:306–311. - PubMed
    1. Savage P, Cooke R, OʼNions J. et al.Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol. 2015;33:472–478. - PubMed